Daniel Prieto-Alhambra (Erasmus MC), Tara Srouji (Novo Nordisk), and Annika Jödicke (University of Oxford)
GREG’s Project Coordinator, Daniel Prieto-Alhambra, and Academic Co-Lead Annika Jödicke, took the stage at DIA Europe 2026 to present the project’s groundbreaking approach to real-world evidence (RWE) generation—highlighting how GREG is bridging the gap between real-world data and regulatory decision-making.
As one of the leading forums for drug development and regulatory science, DIA Europe brought together regulators, industry leaders, and researchers to explore innovative approaches to clinical trials, HTA, and patient-centric evidence.
In a special session, chaired by GREG’s Daniel Prieto-Alhambra, Annika Jödicke presented GREG’s aims and objectives in a talk titled “Fit-for-purpose RWD: Feasibility in IHI GREG”. The session particularly highlighted the work done in collaboration with the EHDEN Foundation to develop a standardized process for feasibility assessment and documentation, as well as the important role the Patient Advisory Group will have ensuring strong patient involvement and engagement in GREG.
Conferences like DIA Europe are catalysing GREG’s mission through engagement with key regulators and industry stakeholders, fostering partnerships with similar initiatives and amplifying patient and clinician voices, ensuring GREG’s tools are practical and user-centred.
Stay tuned for more updates—and see how GREG is redefining RWE for regulatory success!
